Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu.
/PRNewswire/ Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the.
Thames Ventures VCT 2 PLCLEI: 21380035MV1VRYEXPR9531 July 2023Final Results for the year ended 31 March 2023 31 March 202331 March 2022 PencePence Ventures Share pool Net Asset Value per.
/PRNewswire/ Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, is pleased.
Invizius Limited, a Motherwell, Scotland, UK-based biotechnology company developing treatments to suppress unwanted innate immune responses, closed Series A financing of £5.3m.
The round was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Series A remains open to other investors until June 2021.
The company intends to use the funds to complete a First-in-Man safety study in 2022 of its H-Guard
® Priming Solution to reduce the life-threatening inflammatory effects of haemodialysis.
Led by Richard Boyd, Chief Executive Officer, Invizius is a late pre-clinical-stage biotechnology company developing treatments to suppress unwanted innate immune responses, focused initially on reducing the life-threatening inflammatory effects of dialysis. Founded in 2017, the University of Edinburgh spin-out is de